Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder

Por Atkinson, Sarah, Lubaczewski, Shannon, Ramaker, Sara, England, Richard D., Wajsbrot, Dalia B., Abbas, Richat, Findling, Robert L.
Publicado no J Child Adolesc Psychopharmacol (2018)

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder

Por Weihs, Karen L., Murphy, William, Abbas, Richat, Chiles, Deborah, England, Richard D., Ramaker, Sara, Wajsbrot, Dalia B.
Publicado no J Child Adolesc Psychopharmacol (2018)

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder

Por Katzman, Martin A., Nierenberg, Andrew A., Wajsbrot, Dalia B., Meier, Ellen, Prieto, Rita, Pappadopulos, Elizabeth, Mackell, Joan, Boucher, Matthieu
Publicado no J Clin Psychopharmacol (2017)

Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study

Por Wigal, Sharon B., Childress, Ann, Berry, Sally A., Belden, Heidi W., Chappell, Phillip, Wajsbrot, Dalia B., Nagraj, Praneeta, Abbas, Richat, Palumbo, Donna
Publicado no J Child Adolesc Psychopharmacol (2018)